ResearcherUniversity of MiamiNo recent work listed
Jessica MacIntyre
Matched on OpenAlex author ID A5083158412. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper
Papers 7
- The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2017.10.12↗
- Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2015.08.010↗
- A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Co-author DOI 10.1007/s00280-014-2414-z↗
- A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1097/coc.0b013e3182436e8c↗
- Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Co-author DOI 10.1097/coc.0b013e31821862fb↗
- A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. First author DOI 10.1186/1471-2407-12-199↗
- Metastatic pancreatic cancer: what can nurses do? Co-author DOI 10.1188/11.cjon.424-428↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jaime Rafael Merchan · 6 shared papers, 2012–2018 · strength 0.25
- Paper The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. DOI 10.21037/jgo.2017.10.12↗
- Paper A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTer… DOI 10.1007/s00280-014-2414-z↗
- Paper Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic ade… DOI 10.1016/j.pan.2015.08.010↗
- Peter J. Hosein · 4 shared papers, 2012–2018 · strength 0.18
- Paper The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. DOI 10.21037/jgo.2017.10.12↗
- Paper Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic ade… DOI 10.1016/j.pan.2015.08.010↗
- Paper A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. DOI 10.1097/coc.0b013e3182436e8c↗
- Caio M. Rocha Lima · 3 shared papers, 2013–2018 · strength 0.15
- Paper The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. DOI 10.21037/jgo.2017.10.12↗
- Paper Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic ade… DOI 10.1016/j.pan.2015.08.010↗
- Paper A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. DOI 10.1097/coc.0b013e3182436e8c↗
- Gilberto De Lima Lopes Jr. · 3 shared papers, 2012–2014 · strength 0.10
- Paper A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTer… DOI 10.1007/s00280-014-2414-z↗
- Paper A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. DOI 10.1097/coc.0b013e3182436e8c↗
- Paper Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. DOI 10.1097/coc.0b013e31821862fb↗
- Caio Rocha‐Lima · 3 shared papers, 2012–2014 · strength 0.10
- Paper A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTer… DOI 10.1007/s00280-014-2414-z↗
- Paper Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. DOI 10.1097/coc.0b013e31821862fb↗
- Paper A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic ad… DOI 10.1186/1471-2407-12-199↗
- Sofia Palacio · 1 shared paper, 2018 · strength 0.08
- Danny Sleeman · 2 shared papers, 2012–2015 · strength 0.07
- Govindarajan Narayanan · 2 shared papers, 2012–2015 · strength 0.06
- Paper Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic ade… DOI 10.1016/j.pan.2015.08.010↗
- Paper A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic ad… DOI 10.1186/1471-2407-12-199↗
- Lorraine Portelance · 2 shared papers, 2012–2015 · strength 0.06
- Paper Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic ade… DOI 10.1016/j.pan.2015.08.010↗
- Paper A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic ad… DOI 10.1186/1471-2407-12-199↗
- Soley Bayraktar · 1 shared paper, 2014 · strength 0.04
- Heloisa Prado Soares · 1 shared paper, 2014 · strength 0.04
- Moh'd M. Khushman · 1 shared paper, 2015 · strength 0.04
- Ching-Wei David Tzeng · 1 shared paper, 2015 · strength 0.04
- Alberto J. Montero · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.